Therefore, the development of molecularly defined, homogeneous TLR4 agonists which are safe and well tolerated in humans as potential stand-alone therapeutics for cancer or as supplements in checkpoint inhibitor treatment is highly required. This evidence concerns the gene TLR4 and cancer.